INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

Protein phosphorylation is a critical regulatory mechanism utilized by the cell to regulate a myriad of different enzyme reactions and signaling pathways. The steady-state phosphorylation status of a protein is regulated through the combined activities of kinases and phosphatases. Protein phosphatase 2A (PP2A) (40, 46, 54) is the major cellular serine/threonine phosphoprotein phosphatase and plays important roles in regulating the cell cycle (32, 48), apoptosis (16), transcription (1), translation (6), and signal transduction (19). PP2A consists of three subunits: a 36-kDa catalytic C subunit, a 60-kDa regulatory A subunit, and a regulatory B subunit. PP2A can exist in the form of either AC core dimer (PP2A_c) or heterotrimeric ABC holoenzyme. Free C subunit is not found in the cell. Generally, PP2A is believed to be a negative regulator of cell growth and possibly a tumor suppressor, since inactivation of the regulatory A subunit due to gene mutation is tumorigenic (53). The regulation of PP2A activity can occur at several levels. Structurally, association of different B regulatory subunits with the AC core dimer can result in altered substrate specificity, catalytic activity, and subcellular localization. There are three structurally unrelated B families, B(B55), B'(B56), and B", each having several closely related proteins and isoforms with tissue-specific expression. PP2A activity is also subject to regulation by posttranslational modification. For example, the catalytic subunit of PP2A can be phosphorylated in vitro by tyrosine kinases, including p60^v-src, p56^tck, epidermal growth factor, and insulin receptor (9). Many of the regulatory B proteins are phosphoproteins (36), but until this study, there was no evidence for a role of B protein phosphorylation in the regulation of PP2A activity.

PKR has long been known to mediate the antiviral activity of interferons. PKR is activated following infection with different viruses and acts to suppress viral replication (for reviews, see references 13, 56, and 57). The antiviral activity of PKR is attributed to its inhibitory phosphorylation of eukaryotic translation initiation factor 2 (eIF2). The kinase activity of PKR is dependent on but not limited to double-stranded RNA (dsRNA) binding (18). PKR has a bipartite structure consisting of (i) an N-terminal dsRNA binding domain which contains two dsRNA binding motifs responsible for dsRNA binding and (ii) an C-terminal catalytic domain (38).

PKR functions in other cellular activities, including growth regulation, transcription, the cell cycle, and cell death. The expression of functional PKR in yeast results in growth inhibition which can be rescued by coexpressing S51A mutant eIF2, which is not phosphorylated by PKR (11). Likewise, overexpression of PKR in mammalian cells arrests cell growth and promotes apoptosis (3). Conversely, overexpression of mutant PKR protein causes the transformation of NIH 3T3 cells into cells having a tumorigenic phenotype (4, 28, 33, 39). However, the mechanisms underlying the effects of PKR on mammalian cell growth remain unclear and likely involve regulatory pathways in addition to eIF2 phosphorylation. For example, PKR plays a role in NF-B activation by dsRNA, tumor necrosis factor alpha, and gamma interferon (56). Mouse embryonic fibroblasts derived from PKR knockout mice show deficient or reduced activation of NF-B or IRF1 by dsRNA or tumor necrosis factor alpha (29, 59). PKR has also been found to physically interact with Stat1 (58), Stat3 (A. Deb and B. R. G. Williams, unpublished data) and p53 (14, 15), and it may regulate the activities of these transcription factors. PKR has also been implicated in cell cycle regulation (61), controlling the induction of apoptosis (3, 17) and regulating stress-activated cell signaling (12, 20, 23).

Clearly, PKR plays an important role in different pathways of cellular activities. However, with the exception of eIF2, substrates mediating the activities of PKR remain to be convincingly identified in vivo. Accordingly, to search for novel substrates for PKR, we performed a yeast two-hybrid screen (34) using a mutant of PKR (L362Q) with reduced kinase activity as bait. One interacting clone encoded a regulatory subunit of PP2A, B56 (37), suggesting an interplay between PKR and PP2A. Here, we identify B56 as a novel substrate of PKR and show that by phosphorylating B56, PKR may modulate PP2A activity, resulting in a potential novel pathway of protein synthesis inhibition.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

Cell culture. Human glioblastoma T98G, fibrosarcoma 2fTGH, uterus carcinoma HeLa S3, monkey kidney COS-1, and murine 3T3-like pkr^+/+ or pkr^/ fibroblasts (C57/BL6 background) were maintained in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum and grown at 37°C with 5% CO₂.

Yeast two-hybrid screen of human HeLa S3 cDNA library. The bait plasmid pGBT9-PKR M3 was constructed by cloning mutant human PKR (M3, L362Q) cDNA (7) into pGBT9 (Clontech) fused to the Gal4 binding domain (Gal4BD). Screening of a HeLa S3 cDNA Gal4 activation domain (Gal4AD) library was performed according to the instructions of the vendor (Clontech).

Construction of the full-length B56 cDNA. The B56 cDNA clone pGAD GH B56N97 isolated from the HeLa S3 Gal4AD cDNA library has a truncation of about 300 bp encoding the N-terminal 97 amino acids of B56. This portion of cDNA was prepared by reverse transcription of total mRNA from HeLa S3 cells by using Superscriptase II (Gibco BRL) with an antisense primer (ZX4-dw [5'TAA TAA CAT ATG TCA GGG CTC TCC AAA AAT CTC AAG]) specific to human B56 cDNA followed by a PCR with primer ZX4-up (5'TAA TAA CAT ATG AGC GTC AGG GCC GCG GAG ATG T) and ZX4-dw. This cDNA product was cloned into pBS II KS via BamHI and EcoRI sites to create pBS-B56N97. A 1.2-kb EcoRI fragment containing the B56 C-terminal cDNA obtained from the original B56 truncation clone pGAD GH B56N97 was then inserted into pBS-B56N97. The resulting construct, pBS-B56, contains a cDNA encoding full-length B56 protein. Recombinant B56 expression plasmid pET28c-B56 was constructed by digesting pBS-B56 with BamHI and XhoI and ligating this BamHI- and XhoI-digested B56 fragment to pET28c (Novagen). B56 protein expressed from this vector has a six-histidine epitope tag followed by a T7 tag in the N terminus. To construct the mammalian expression plasmid pZeoSV-B56, pBS-B56 was digested with BamHI and XhoI and ligated into pZeoSV (Invitrogen).

Recombinant protein preparation and purification. Both glutathione S-transferase-PKR (6) and histidine-tagged recombinant human PKR protein (8) were produced as described previously. Both recombinant B56 and eIF2 were expressed as six-histidine-tagged proteins and purified by affinity chromatography using His-Bind metal chelation resin according to the instructions of the manufacturer (Novagen). B56 was expressed from the pET28c-B56 expression construct in Escherichia coli BL21(DE3)pLysS cells (Novagen), which were grown at 37°C in 500 ml of Luria-Bertani medium containing 30 µg of kanamycin per ml and 34 µg of chloramphenicol per ml and induced by 1.0 mM IPTG (iospropyl--D-thiogalactopyranoside) for 45 min, and purified under natural conditions. Human eIF2 was expressed from pQE-eIF2 (7) in E. coli M15(pREP4) host cells (Qiagen) grown in 4 liters of Luria-Bertani culture and induced with 1 mM IPTG for 4 h and was purified under denaturing conditions. Further purification of eIF2 was performed using a Q Sepharose Fast-Flow anion-exchange column (Pharmacia) with a starting buffer of 50 mM Tris-HCl (pH 7.9) and 50 mM NaCl. After washing of the column with 250 mM NaCl-Tris buffer, eIF2 was eluted by increasing the NaCl concentration to 500 mM. eIF2 protein was concentrated and stored at 80°C after addition of glycerol to 10%.

In vitro phosphorylation assay. (i) Phosphorylation of MBP by PKC. Myelin basic protein (MBP) (100 µg) was phosphorylated with 25 ng of protein kinase (PKC) (Upstate Biotechnology) in 40 µl of assay dilution buffer (20 mM MOPS [morpholinepropanesulfonic acid] [pH 7.2], 25 mM -glycerophosphate, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 1 mM CaCl₂), 10 µl of PKC activator (0.5 mg of phosphatidylserine per ml and 0.5 mg of diglycerides per ml in assay dilution buffer), and 10 µl of ATP mixture (75 mM MgCl₂, 50 µM ATP, 150 µCi of [-³²P]ATP). The reaction was carried out at 30°C for 20 min.

(ii) Phosphorylation of B56 or eIF2 by PKR. Recombinant B56 or eIF2 protein solution (about 200 ng) was mixed with 30 µl of DBGA buffer (10 mM Tris-HCl [pH 7.6], 50 mM KCl, 2 mM Mg acetate, 7 mM 2-mercaptoethanol, 20% glycerol), 20 µl of DBGB buffer (2.5 mM MnCl₂ in DBGA), 5 µl of ATP mixture (10 µM ATP and 1.5 µCi of [-³²P]ATP per ml in DBGA), and 5 µl of poly(rI:rC) (pIC) (12 ng/µl in DBGA). The kinase reaction was carried out at 30°C for 20 min after addition of 100 ng of recombinant PKR to the mixture.

Site-directed mutagenesis of B56. Site-directed mutagenesis of B56 was carried out with a reaction kit from Clontech according to the manufacturer's instructions. To mutate serine 28 of B56 to alanine, mutation primer MP-S28A (5'P-CACCCGGAAAGCGGTCCGCAAG-3') and selection primer B56-pSelect (5'P-GGGGCCCGGTTCCCAGCTTTTG-3' with a mutated KpnI site) were annealed with denatured pBS-FLAG-B56 plasmid DNA. T4 DNA polymerase was added, and following DNA synthesis, the gaps were ligated with T4 DNA ligase. The product was digested with KpnI and transformed into mutS E. coli. Second-round selection was performed by isolating plasmid DNA, digesting with KpnI, and transforming into DH5. Plasmid DNA isolated from individual colonies was analyzed by restriction digestion and sequencing to confirm the success of mutation. Quadruple mutation of B56 (S18A, S28A, S323A, and S436A) was achieved by annealing pBS-FLAG-B56/S28A with mutation primers MP-S18A (5'P-CCA TCT CGG CCG CGG AGA AAG TG-3'), MP-S323A (5'P-GGC CAA AAA CCT GCG CTC AGA AAG AGG TGA TG-3'), and MP-436A (5'P-GAC CTT ACT AGC GCA TAC AAA GCT G-3') and selection primer B56-pSelect2 (5'P-GAT ACC GTC GAG CTC GAG GGG G-3'). B56 mutant fragments were then recloned into the pET28C expression vector, and proteins were expressed and purified as described above.

PAA assay and tryptic phosphopeptide mapping of B56 phosphorylation sites. Two-dimensional separation of phosphoamino acids (PAA) and phosphopeptides of B56 using thin-layer cellulose (TLC) plates was performed as described previously (5). Recombinant B56 was phosphorylated by PKR and labeled in vitro with [-³²P]ATP as described above, and the proteins were separated on a sodium dodecyl sulfate (SDS)-8% polyacrylamide gel, excised from the dried gel, eluted out of the gel slice with 50 mM NH₄HCO₃, and precipitated with 20% cold trichloroacetic acid. For PAA assay, the sample was resuspended in 100 µl of 5.7 M HCl and boiled at 110°C for 1 h. After hydrolysis, the sample was dried in a Speed-Vac (Savant) and resuspended in pH 1.9 buffer (2.2% formic acid and 7.8% acetic acid), which contains 15 parts of buffer to 1 part of cold PAA standards (1.0 mg [each] of phosphoserine, phosphothreonine, and phosphotyrosine per ml) (Sigma). The sample was applied to a TLC plate (C.B.S. Scientific Company, Inc.), and two-dimensional electrophoresis was carried out using the Hunter thin-layer peptide mapping electrophoresis system (model no. HTLE-7000; C.B.S.). The first-dimension separation was done with pH 1.9 buffer at a constant 1,500 V for 30 min, and the second-dimension separation was done in pH 3.5 buffer (5% acetic acid and 2.5% pyridine) at a constant 1,300 V for 25 min. PAA standard colors were developed by spraying 0.25% ninhydrin in acetone and baking the plate at 65°C for 30 min.

In vitro phosphatase assay. Approximately 2 µg of B56 was phosphorylated by PKR as described above. As an unphosphorylated B56 control, the B56 was incubated in the same phosphorylation reaction mixture except that no PKR was added. The reaction mixtures were concentrated and washed with phosphatase reaction buffer (20 mM MOPS [pH 7.2], 25 mM 2-mercaptoethanol, 10 mM MgCl₂, 100 µg of bovine serum albumin per ml) without bovine serum albumin, using a 0.5-ml ultrafree centrifugal filter device spin tube (Biomax 30K NMWL membrane; Millipore), and finally concentrated to 20 µl. For the dephosphorylation of MBP by PP2A AC dimer (PP2A_c), 15 µl of MBP phosphorylation mixture (25 µg of MBP) was diluted to a final volume of 200 µl with phosphatase assay buffer. Dephosphorylation was initiated at 30°C with the addition of 150 ng of PP2A_c (Upstate Biotechnologies). For dephosphorylation of MBP by PP2A-B56, 15 µl of MBP substrate mix was diluted to a final volume of 180 µl with phosphatase assay buffer, and then 20 µl of B56, either phosphorylated or not, was quickly mixed with 150 ng of PP2A_c and added to the reaction mixture. At each time point (1, 2, 5, 10, and 20 min), 40 µl was sampled and 5 µl of 10× PP2A stop solution (50 mM EDTA, 1 M NaF, 20 mM NaPP_i) was added. All samples were analyzed on SDS-polyacrylamide gels and exposed for PhosphorImager (Molecular Dynamics) analysis. Protein phosphorylation was quantitated by ImageQuant version 1.1 software after scanning the screen using a Storm PhosphorImager (Molecular Dynamics). For the eIF2 dephosphorylation assay, recombinant eIF2 (10 µg) was phosphorylated by PKR in vitro, and the phosphorylation reaction product was washed with phosphatase reaction buffer and concentrated to 40 µl. For each phosphatase assay, 12 µl of eIF2 (3 µg) was used. The rest of the procedure was as for the MBP dephosphorylation assay described above.

Coimmunoprecipitation of human PKR with B56. Human glioblastoma T98G cells were lysed with immunoprecipitation lysis buffer (50 mM HEPES [pH 7.5], 0.5% NP-40, 150 mM NaCl, 2 mM EDTA, 10% glycerol, 1 mM dithiothreitol, 1 mM phenyl methyl sulfonyl fluoride, 5 µg of leupeptin per ml, 2 µg of aprotinin per ml) on ice for 30 min. The crude lysate was cleared by centrifugation at 14,000 × g for 20 min, and the supernatant was collected. To assay the endogenous association between PKR and B56, 1 to 3 mg of protein extract was used for immunoprecipitation with an antibody against human PKR (61). After addition of antibody, the lysate was incubated on ice for 30 min and mixed with 40 µl of protein G-conjugated Sepharose resin (Pharmacia), and the mixture was agitated at 4°C overnight then washed with immunoprecipitation lysis buffer. The proteins were separated with SDS-8% polyacrylamide gel and transferred to an Immobilon-P membrane (Millipore). Western blotting was performed using a polyclonal antibody against human B56 (Santa Cruz). To assay kinase activation-dependent association of PKR with recombinant B56, T98G cell extract (200 µg) was immunoprecipitated with a monoclonal antibody against human PKR as described above. After washing with immunoprecipitation lysis buffer, the immunoprecipitates were washed three times with DBGA buffer. Recombinant histidine-tagged B56 (1 µg) in 60 µl of kinase reaction buffer (10 mM Tris-HCl [pH 7.6], 50 mM KCl, 2 mM Mg acetate, 7 mM 2-mercaptoethanol, 0.83 mM MnCl₂, 100 µM ATP, 20% glycerol) either with or without pIC (1 ng/µl) was added to the immunoprecipitates, and the mixture was incubated at 30°C for 20 min. Following washing with DBGA buffer, the proteins were separated with an SDS-8% polyacrylamide gel and analyzed by Western blot assay using a polyclonal antibody against human B56. The membrane was stripped and reprobed with a polyclonal antibody against human PKR. T98G and 2fTGH cells (2 × 10⁶) were also transfected with 4 µg of FLAG-B56 expression plasmid DNA (pZeoSV-FLAG-B56) using Lipofectamine (Gibco BRL). After 24 h of transfection, the cells were treated with 100 µg of pIC per ml in the presence of 100 nM okadaic acid for 1 h. The cell lysates were prepared with cell lysis buffer, and 2-mg cell lysates were used for immunoprecipitation of FLAG-B56 with anti-FLAG M2 affinity gel (Sigma). The gel was washed with cell lysis buffer after agitation at cold room overnight, and the association of PKR was analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting using a polyclonal antibody.

Preparation of endogenous PP2A. Cell extracts was prepared from HeLa S3 cells as described above. Anti-human PP2A C subunit polyclonal antibody (4 µg) (Upstate Biotechnologies) was added to 200 µg of cell extract and incubated on ice for 30 min. Protein G-Sepharose beads were mixed with the extract and agitated at 4°C overnight, and the immunoprecipitates were washed with immunoprecipitation lysis buffer and used in the kinase assay described above.

IEF-SDS-PAGE two-dimensional analysis of protein phosphorylation. Human 2fTGH cells and murine 3T3-like pkr^+/+ or pkr^/ fibroblasts (2 × 10⁶) were transfected with 4 µg of FLAG-B56 expression plasmid DNA pZeoSV-FLAG-B56 using Lipofectamine reagent. After 24 h of transfection, the cells were treated with 100 µg of pIC per ml in the presence of 100 nM okadaic acid for 1 h. The cells were lysed with cell lysis buffer, and 2 mg of cell lysate was used for immunoprecipitation of FLAG-B56 with anti-FLAG M2 affinity gel. FLAG-B56 was eluted from the gel by adding 125 µl of rehydration buffer {8 M urea, 4% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate [CHAPS], 10 mM dithiothreitol, 0.2% Bio-Lytes 3/10}. IPG strips (7 cm, pH 5 to 8; Bio-Rad) were rehydrated with rehydration buffer containing FLAG-B56 for 12 h before running isoelectric focusing (IEF). The IEF electrophoresis was performed with a Protean IEF Cell (Bio-Rad) according to the instruction manual. Focusing was carried out with 250 V for 15 min with a linear increase from 250 to 4,000 V for 2 h and 4,000 V for 5 h. After focusing, the strips were laid on top of SDS-polyacrylamide gels for second-dimension separation. B56 was examined by Western blotting using a polyclonal antibody against B56 as mentioned above. eIF4E phosphorylation was assayed from 2fTGH cells which were lysed directly with rehydration buffer. About 300 µg of cell lysate was reabsorbed into 17-cm IPG strips (pH 3 to 10), and IEF-PAGE separation was performed as described above. Western blotting of eIF4E was performed using a monoclonal antibody against rabbit eIF4E (Transduction Laboratories, Lexington, Ky.).

Transfection assays of exogenous luciferase expression. COS-1 cells were plated in six-well plates at 3 × 10⁵ cells per well. The following day six duplicated plates were transfected with 200 ng of luciferase reporter construct pGL2p (Promega), 1.5 µg of pZeoSV-B56 or pZeoSV vector, and 1.0 µg of either pRC-PKR, pRC-PKR(K296R), or pRC vector. The cells were transfected for 3 h using Lipofectamine Plus (Gibco BRL) according to manufacturer's instructions. After 24 h, the cells were lysed with 300 µl of 1× reporter lysis buffer (Promega), and 40 µl of cell extract was assayed for luciferase activity. To examine the effect of okadaic acid on protein expression, cells were transfected with pGL2p (200 ng) in the presence or absence of okadaic acid (100 nM). After 3 h, the medium was replaced with complete Dulbecco modified Eagle medium with or without 100 nM okadaic acid and incubated for a further 4 h. Cell extracts were prepared and luciferase activity was measured as described above. Transfection treatment of murine 3T3-like fibroblasts followed same protocol with the amount of DNA described in the legend to Fig. 7. Okadaic acid treatment of fibroblasts lasted overnight, as they are more resistant to okadaic acid-induced apoptosis than COS-1 cells.

RT-PCR detection of luciferase mRNA. 3T3-like pkr^+/+ cells were cotransfected with 500 ng of pGL2p and 1 µg of pZeoSV-B56 or pZeoSV as described earlier. The cells which were transfected with vector pZeoSV either were left untreated or were treated with 50 nM okadaic acid for 24 h. DNA-free mRNA was isolated from the cells by using a High Pure RNA Isolation Kit (Boehringer Mannheim). Reverse transcription (RT) was performed with Superscript II from 1 µg of RNA sample according to the instructions of the manufacturers (Gibco BRL). PCR of luciferase or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was carried out with 1/10 of the RT sample, using 30 cycles of denaturation at 94°C for 20 s, renaturation at 55°C for 20 s, and extension at 72°C for 30 s. Real-time SYBR Green PCR was performed according to the instructions of the manufacturer (Perkin-Elmer Applied Biosystems).

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

Identification of B56 as a PKR-interacting protein. To identify PKR-interacting proteins, we performed a yeast two-hybrid screen of a human HeLa S3 Gal4AD fusion cDNA library using mutant PKR M3 (L362Q) Gal4BD fusion protein as bait. Since wild-type PKR inhibits yeast cell growth (11), previous two-hybrid screens have used catalytically inactive PKR (42). However, we reasoned that kinase activity may be important for PKR substrate interactions and therefore selected an L362Q mutant PKR which exhibits low residual autophosphorylation activity but does not inhibit yeast growth (7). A primary screen of the library identified 30 histidine-positive clones, 10 of which were positive for -galactosidase expression. The cDNAs from these clones were sequenced, and a BLAST search against nonredundant human nucleotide sequences in the National Center for Biotechnology Information database identified two known proteins, while the remainder represented novel genes. The identified proteins are PP2A regulatory subunit B56 (37) and P76, also known as NF90 (26) or M-phase phosphoprotein 4 (35). P76 was also identified as a dsRNA-interacting protein and shown to be phosphorylated by PKR (43). Since B56 is a regulatory subunit of PP2A, we hypothesized that the interaction between PKR and B56 may represent a mechanism by which PKR regulates PP2A activity.

B56 is a substrate for PKR in vitro. The B56 cDNA obtained from the initial library screen encoded a B56 protein with a truncation of 97 amino acids from the amino terminus (37). A full-length B56 cDNA was constructed by ligation with a cDNA fragment encoding the corresponding amino-terminal peptide (see Materials and Methods), and the recombinant protein was tested for dsRNA-dependent phosphorylation by recombinant human PKR. In the absence of the dsRNA analog pIC, recombinant PKR exhibited only a low level of kinase activity which was insufficient to phosphorylate B56. However, when PKR was activated by dsRNA, B56 was phosphorylated to a high level (Fig. 1A). Phosphorylation of B56 can be also achieved by using glutathione S-transferase fusion human PKR (data not shown).

View larger version (35K): [in this window] [in a new window]   FIG. 1.   Assay of substrate phosphorylation of B56 and eIF2 by PKR. The proteins were separated by SDS-PAGE and visualized by autoradiography. (A) Phosphorylation of B56 by recombinant His-PKR in vitro. Recombinant B56 (200 ng) was mixed with 100 ng of recombinant human PKR in kinase reaction buffer either in the presence (lane 3) or in the absence (lane 2) of pIC. PKR autophosphorylation is shown in lane 1. (B) Comparison of the substrate phosphorylation of eIF2 and B56 by PKR. About 200 ng of recombinant B56 (lanes 3 and 4) or eIF2 (lanes 1 and 2) was reacted with 100 ng of recombinant PKR in kinase reaction buffer either in the presence (lanes 1 and 3) or in the absence (lanes 2 and 4) of pIC. The weaker autophosphorylation of PKR in the presence of eIF2 was due to impurity in the eIF2 preparation (data not shown).

B56 is multiple phosphorylated on serine and threonine by PKR. PKR has been characterized as a Ser/Thr kinase, but no consensus phosphorylation site has been described. To determine if B56 was phosphorylated on Ser/Thr by PKR, a PAA assay was performed on phosphorylated protein. Recombinant B56 was phosphorylated by PKR in vitro and hydrolyzed by boiling HCl. The PAA were analyzed by two-dimensional thin-layer electrophoresis. Compared with PAA standards (Fig. 2A, left panel), PKR phosphorylates B56 mainly on serine residues and to a lesser extent also on threonine (Fig. 2A, right panel).

View larger version (37K): [in this window] [in a new window]   FIG. 2.   PAA assay (A) and peptide mapping (B) of B56 phosphorylation sites by PKR. (A) B56 was radioactively phosphorylated by PKR in vitro and acid hydrolyzed. Amino acids were separated on a TLC plate. PAA standards (p-Ser, p-Thr, and p-Tyr) were also loaded and visualized by color reaction with 0.25% ninhydrin in acetone (left panel). PAA in B56 phosphorylation by PKR were visualized by autoradiography (right panel). ppi, free phosphate. (B) Wild-type (panel 1), single point mutant (S28A) (panel 2), or quadruple point mutant (S18AS28AS323AS436A) (panel 3) B56 was radioactively phosphorylated by PKR in vitro and digested with TPCK-trypsin. Peptides were separated on TLC plates with electrophoresis at the first dimension and chromatography in the second dimension. The positions of phosphopeptides were visualized by autoradiography. The individual peptides were labeled as shown.

Physical association between PKR and B56 requires kinase activity of PKR. Although recombinant B56 is an efficient substrate for activated PKR, there is an absence of basal phosphorylation of B56 by latent recombinant PKR (Fig. 1). To determine whether activation of PKR was necessary to allow interaction with B56, we immunoprecipitated endogenous PKR from T98G cell extracts, activated this with dsRNA, and added recombinant B56. Physical association between PKR and B56 can be detected only under conditions where PKR is activated (Fig. 3A).

View larger version (93K): [in this window] [in a new window]   FIG. 3.   Physical interaction between PKR and B56. (A) PKR was immunoprecipitated (IP) with monoclonal antibody from 200 µg of T98G cell extract, either activated (lane 2) or not activated (lane 1) by pIC. Recombinant B56 was added and the immunoprecipitates were washed, followed by SDS-PAGE and Western blotting assay with a polyclonal antibody against B56 (top panel). The blot was stripped and reprobed with a polyclonal antibody against human PKR (bottom panel). (B) In vivo association between PKR and B56. PKR was immunoprecipitated with monoclonal antibody from 3 (lane 1), 2 (lane 2), and 1 (lane 3) mg of T98G cell extract, respectively. The proteins were separated by SDS-PAGE, transferred to a membrane, and immunoblotted with a polyclonal antibody against human B56. Cell extract (3 mg) without addition of anti-PKR monoclonal antibody was used as a negative control (lane 4). Recombinant His-T7 B56 was used as a positive control (lane 5). The lack of endogenous B56 in panel A is likely due to the less amount of cell lysate. (C) Autophosphorylation of PKR in human T98G and 2fTGH cells in response to pIC treatment. Human T98G and 2fTGH cells were treated with pIC (100 µg/ml) for 1 h. PKR was immunoprecipitated from 150 µg of cell lysate with monoclonal antibody. The kinase activity of PKR was assayed in an in vitro autophosphorylation reaction in the presence of [-32P]ATP. (D) Western blot assay of PKR protein levels in cells either treated or not treated with pIC. T98G or 2fTGH cells were either treated or not treated with 100 µg of pIC per ml as described above, and 150 µg of total cell lysate was assayed for PKR protein level by Western blotting using a polyclonal antibody against human PKR. (E) Activation of PKR in cells by pIC increases its affinity with B56. Human T98G or 2fTGH cells were transfected with FLAG-B56 expression plasmid DNA (pZeoSV-FLAG-B56) (lanes 1, 2, 6, and 7) or vector DNA (pZeoSV) (lanes 3 and 8). Cells were treated with 100 µg of pIC per ml for 1 h (lanes 2 and 7). Immunoprecipitation of FLAG-B56 was performed with anti-FLAG M2 affinity gel, and the association of PKR was detected by Western blotting using an anti-human PKR polyclonal antibody (top panel). Recombinant His-T7-B56 (lane 4) and His-PKR (lane 5) were also included as positive controls. The polyclonal antibody against human PKR has cross-reaction with His-T7-B56 because His-PKR was used as a source to generate the polyclonal antibody. The membrane was also stripped and reprobed with anti-human B56 polyclonal antibody to examine B56 protein levels (bottom panel).

Activation of PKR alters the isoelectric point of B56. B56 is a substrate for PKR in vitro and shows increased association with PKR upon PKR activation in cells. This suggests that B56 should be a physiological substrate for PKR in vivo. Accordingly, we investigated whether the activation of PKR in the cell resulted in a change in the phosphorylation level of B56. Human 2fTGH fibroblasts were transfected with FLAG-tagged B56 expression plasmid DNA and treated with pIC to activate PKR protein. B56 was immunoprecipitated from cell lysates and analyzed by two-dimensional IEF and SDS-PAGE to determine the phosphorylation-induced change in its isoelectric point (pI). The pI of B56 from untreated cells spans a range from 6.2 to 6.8, suggesting that B56 is phosphorylated at multiple sites, consistent with the results of B56 phosphopeptide maps in vitro. Treatment of cells with the PKR activator pIC caused a shift in the pI of B56 toward a lower pH value, indicating an increase in acidic forms of B56, likely due to phosphorylation (Fig. 4A). To assess the possibility that the pIC-induced pI shift in B56 is dependent on PKR, we transfected pkr^+/+ or pkr^/ fibroblasts with FLAG epitope B56 expression plasmid DNA and examined the pI status of FLAG-B56 after treatment of the cells with pIC (Fig. 4B). The pI of B56 in murine fibroblasts ranges from 5.2 to 6.8. Treatment of pkr^+/+ cells with pIC caused a pI shift in B56, with an increase its acidic forms compared with untreated cells. This change is not observed in pkr^/ cells. These observations indicate that the pIC-induced pI shift of B56 toward acidic forms in cells results from phosphorylation of B56 by pIC-activated PKR.

View larger version (60K): [in this window] [in a new window]   FIG. 4.   Mobility shift of B56 in IEF in response to pIC treatment of the cell. (A) Human 2fTGH cells were transfected with FLAG-B56 expression plasmid DNA pZeoSV-FLAG-B56. The cells were either treated (bottom panel) or not treated (top panel) with 100 µg of pIC per ml to activate PKR. B56 was immunoprecipitated from 2 mg of cell lysate and separated in the first dimension with IEF in a ready-strip IPG strip (pH range, 5 to 8; Bio-Rad) and in the second dimension with an SDS-polyacrylamide gel. Western blotting with a polyclonal antibody against human B56 was performed to detect B56. Recombinant His-T7-B56 was loaded at the rightmost side and used as reference for alignment. B56 from 2fTGH cells showed pI values varying from 6.2 to 6.8, but it is very likely that more acidic forms of B56 failed to be detected because of a lower expression level of B56 in 2fTGH cells compared with murine fibroblasts in panel B. (B) pI of FLAG-B56 from pkr+/+ or pkr/ cells treated or not treated with pIC. The experimental procedure is same as for 2fTGH cells in panel A. The pI values range from 5.3 to 6.8.

Phosphorylation of B56 by PKR modulates PP2A activity. B56 is a regulatory subunit of PP2A and has been found to tightly associate with PP2A_c (37). Although it is also a phosphoprotein in vivo, it is not clear whether this phosphorylation plays a role in regulating PP2A activity. To determine if B56 phosphorylation by PKR could regulate PP2A activity in vitro, a phosphatase activity assay was performed using MBP phosphorylated by PKC as the substrate for PP2A (Fig. 5A). The phosphatase activities of three forms of PP2A were compared. PP2A_c was commercially obtained. PP2A_c-B56, which is a trimeric holoenzyme with unphosphorylated B56 as the regulatory subunit, was prepared by mixing recombinant B56 with PP2A_c. PP2A_c-B56-p, which is a trimeric holoenzyme with phosphorylated B56 as the regulatory subunit, was prepared by mixing PKR-phosphorylated B56 with PP2A_c. Excess B56 was added to ensure that PP2A existed as the form of AC-B56 trimeric holoenzyme. The results (Fig. 5A and B) show that whereas unphosphorylated B56 decreased PP2A_c activity on MBP, phosphorylation of B56 by PKR blocked this effect and increased the phosphatase activity of PP2A_c-B56 holoenzyme. Thus, PP2A_c-B56 holoenzyme was less active than PP2A_c, but when B56 was phosphorylated by PKR, phosphatase activity on MBP was enhanced. Similar results were obtained when recombinant eIF2 protein phosphorylated by PKR was used as a substrate for PP2A (Fig. 5C and D), although the recombinant eIF2 is a less efficient substrate for PP2A than MBP.

View larger version (102K): [in this window] [in a new window]   FIG. 5.   Modulation of PP2A activity on MBP or eIF2 via phosphorylation of B56 by PKR. (A) In vitro PP2A activity on PKC-phosphorylated MBP. MBP was phosphorylated by PKC with radioactive ATP ([-32P]ATP) and used as a substrate for PP2A (either PP2Ac dimer, PP2Ac-B56, or phosphorylated PP2Ac-B56). B56 either phosphorylated or not by PKR was quickly premixed with PP2Ac to generate the PP2Ac-B56 or PP2Ac-B56-p form of PP2A. Dephosphorylation was carried out at 30°C, and equal amounts of reaction mixture were taken out after 1, 2, 5, 10, and 20 min. The reaction was stopped by adding phosphatase stop solution and separated by SDS-12% PAGE. Lane 1, starting level of MBP phosphorylation; lanes 2 to 16, time courses of dephosphorylation of MBP; lane 17, input of PKR and B56 in PP2Ac-B56-p reaction. (B) Quantitation of the data in panel A. MBP phosphorylation levels were quantitated by ImageQuant version 1.1 analysis following scanning of the gel with a Storm PhosphorImager. (C) In vitro PP2A activity on PKR-phosphorylated eIF2. Recombinant eIF2 was phosphorylated by recombinant PKR with radioactive ATP ([-32P]ATP) and used as a substrate for PP2A (either AC dimer PP2Ac, PP2Ac-B56, or PP2Ac-B56-p). Dephosphorylation of eIF2 was carried out in the same way as for MBP dephosphorylation. Lane 1, starting level of eIF2 phosphorylation; lanes 2 to 6, time course of dephosphorylation of eIF2 by PP2Ac core dimer; lanes 7 to 11, time course of dephosphorylation of eIF2 by PP2Ac-B56; lanes 12 to 16, time course of dephosphorylation of eIF2 by PP2Ac-B56-p; lane 17, Input of PKR and B56 in PP2Ac-B56-p reaction. (D) eIF2 phosphorylation levels were quantitated by ImageQuant version 1.1 analysis following scanning of the gel with a Storm PhosphorImager. The abnormal eIF2 phosphorylation percentage with PP2Ac-B56 and PP2Ac-B56-p at the 5-min time point is likely due to the undermeasurement of the initial eIF2 phosphorylation.

B56 is a target for dephosphorylation by PP2A. In the in vitro phosphatase activity assay, we observed that the phosphorylation level of B56 was progressively reduced over time, suggesting that B56 itself can be dephosphorylated by PP2A (Fig. 5). This observation was confirmed by an in vitro B56 dephosphorylation assay using immunoprecipitated PP2A (Fig. 6). When okadaic acid was included to inhibit PP2A activity, PKR was able to phosphorylate B56 to a maximal level as determined by labeling with [-³²P]ATP, whereas in the absence of okadaic acid, B56 phosphorylation was greatly reduced. The finding that B56 is a target for PP2A suggests that there is an autoregulatory mechanism for PP2A activity.

View larger version (64K): [in this window] [in a new window]   FIG. 6.   Phospho-B56 is dephosphorylated by PP2A. Endogenous PP2A was immunoprecipitated from HeLa S3 cells and mixed with recombinant B56 phosphorylated by PKR in the presence or absence of 5 nM okadaic acid at 30°C for 20 min. The proteins were separated on an SDS-polyacrylamide gel, and an autoradiograph of the dried gel is shown.

PKR inhibits the stimulatory effect of B56 on protein expression. The identification of B56 as a novel PKR substrate that physically associates with PKR begs the question of the physiological significance of this interaction. Although B56 may direct PP2A to regulate the phosphorylation status and the activity of PKR, the activity of PP2A on PKR is weak (Fig. 6). Since in vitro phosphatase activity assays showed that phosphorylation of B56 by PKR could modulate PP2A activity, we hypothesized that PKR can alter PP2A activity by phosphorylating B56 and affect downstream cellular activities. However, a direct assay of PP2A phosphatase activity immunoprecipitated from the human cells treated with pIC did not show much difference from that from untreated cells (data not shown). This is not unexpected, since B56 is also likely a target for dephosphorylation by PP2A itself (Fig. 6). Therefore, we sought an alternate way to examine the alteration of PP2A activity in vivo resulting from the interaction between PKR and B56. We found that treatment of cells (COS-1, pkr^+/+, or pkr^/ fibroblasts) with the PP2A inhibitor okadaic acid resulted in enhanced expression from a transfected luciferase reporter plasmid, pGL2p, whose luciferase expression is driven by a constitutive simian virus 40 promoter (Fig. 7A). This effect can be observed with a concentration of okadaic acid of less than 10 nM (Fig. 7B). Since PP2A is much more sensitive to okadaic acid than PP1 is, these results support a role for PP2A in regulating protein expression. To examine if overexpression of B56 could influence PP2A activity in this assay and if this activity could be modulated by coexpression with PKR, we cotransfected COS-1 cells with pGL2p and a construct expressing B56 (pZeoSV-B56), wild-type human PKR (pRC-PKR), or dominant-negative mutant PKR K296R (pRC-K296R) (Fig. 7C, left panel). Since translational control by PKR mediated through eIF2 phosphorylation is a well-established PKR function, luciferase expression in transfected COS-1 cells will be altered by expression of PKR alone (7, 60). In accord with previous reports, wild-type PKR reduces luciferase expression in this assay whereas cotransfection with catalytically inactive PKR results in enhanced expression from the reporter (Fig. 7C, bars 3 and 5). Transfection with the B56 expression construct alone resulted in enhanced luciferase expression, which could be abrogated by coexpression of wild-type PKR (Fig. 7C, bars 2 and 4). Cotransfection of B56 with mutant PKR K296R resulted in striking enhancement of protein synthesis (Fig. 7C, bar 6). These results suggest that overexpression of B56 in COS-1 cells is able to modulate PP2A activity to enhance protein synthesis. This effect can be inhibited by PKR, most likely via a functional interaction with and phosphorylation of B56 by PKR. This observation was confirmed when the experiment was repeated with a murine fibroblast cell line in which the effect of B56 is completely suppressed when cotransfection is with wild-type PKR (Fig. 7C, right panel). The PKR-dependent modulation of PP2A activity was supported by comparing the luciferase expression in pkr-null cells transfected with B56 with that in wild-type cells transfected with B56. The results show that B56 is more active in the absence of PKR (Fig. 7D).

View larger version (68K): [in this window] [in a new window]   FIG. 7.   Stimulation of protein synthesis by B56 is inhibited by PKR. (A) The PP2A inhibitor okadaic acid (OA) stimulates exogenous luciferase expression in cells. COS-1 (left panel), pkr+/+ (middle panel), or pkr/ (right panel) cells were transfected with luciferase expression vector pGL2p (200 ng in COS-1 cells and 500 ng in 3T3-like cells) and treated with 100 nM OA (right bars) or left untreated (left bars). Six duplicate samples were prepared for COS-1 cells, and four duplicate samples were prepared for fibroblasts. (B) OA sensitivity assay of exogenous luciferase expression in pkr+/+ cells. pkr+/+ cells were transfected with 200 ng of luciferase expression vector pGL2p and treated with different concentrations of OA. Luciferase units were measured after 24 h of transfection and plotted as relative units against an untreated control. Triplicate samples were assayed. (C) A luciferase reporter, pGL2p (200 ng), was cotransfected into COS-1 cells (left panel) with B56 expression construct pZeoSV-B56 (bars 2, 4, and 6) (1.5 µg), wild-type PKR expression construct pRC-PKR(wt) (bars 3 and 4) (1 µg), or mutant PKR construct pRC-PKR(K296R) (bars 5 and 6) (1 µg). pGL2p (200 ng) was cotransfected into pkr+/+ cells (right panel) with B56 expression construct pZeoSV-B56 (bars 2, 4, and 6) (0.5 µg), wild-type PKR expression construct pRC-PKR(wt) (bars 3 and 4) (0.5 µg), or mutant PKR construct pRC-PKR(K296R) (bars 5 and 6) (0.5 µg). Cell extracts were prepared 24 h after transfection and assayed for luciferase activity, and the values from the means of six (COS-1) or three (pkr+/+) duplicate samples were plotted. (D) Increased expression of exogenous luciferase in pkr/ cells transfected with B56. pkr-null cells and wild-type cells were transfected with 200 ng of pGL2p. The cells were also cotransfected with 1 µg of either pZeoSV--gal or pZeoSV-B56. Luciferase units were measured in 24 h after the start of transfection. The mean value from four duplicate samples each was plotted. Error bars indicate standard deviations.

PKR may modulate PP2A activity to regulate eIF4E phosphorylation. The phosphorylation of eIF2 to inhibit protein translation is a well-established mechanism for PKR-dependent regulation of protein translation. However, the luciferase transfection assay results (Fig. 7) indicate that there is likely a novel mechanism involving PKR upregulation of PP2A activity. When the luciferase mRNA levels in pkr^+/+ cells transfected with pGL2p were compared with those in transfected cells treated with okadaic acid or cells which were also cotransfected with B56 by RT-PCR (Fig. 8) or by SYBR Green assay (data not shown), no obvious changes in luciferase mRNA levels were seen, indicating that PP2A is acting at the translational level. Since phosphorylation of eIF4E at serine 209 (25, 31) plays an important role in protein translation initiation, we examined whether expression of B56 or activation of PKR can regulate eIF4E dephosphorylation. Untreated cell extracts analyzed by IEF-PAGE revealed a high percentage of unphosphorylated eIF4E (Fig. 9, panel 1). Treatment with okadaic acid caused an increased level of eIF4E phosphorylation (Fig. 9, panel 2), consistent with enhanced protein translation (Fig. 7). Transfection of 2fTGH cells with B56 expression DNA also resulted in an increased level of eIF4E phosphorylation, likely due to decreased PP2A activity (Fig. 9, panel 3). Interestingly, when 2fTGH cells transfected with a B56 expression plasmid were treated with pIC to activate PKR, the eIF4E phosphorylation level was decreased compared with that in untreated cells (Fig. 9, panel 4). These data suggest that PKR can phosphorylate B56 to increase PP2A activity, resulting in decreased eIF4E phosphorylation.

View larger version (38K): [in this window] [in a new window]   FIG. 8.   RT-PCR assay of luciferase mRNA. pkr+/+ cells were cotransfected with 500 ng of pGL2p and 1 µg of pZeoSV (DNA samples 1, 2, 3, and 4 [lanes 1, 2, 3, 4, 7, 8, 9, 10, 13, 14, 15, and 16]) or pZeoSV-B56 (DNA samples 5 and 6 [lanes 5, 6, 11, 12, 17, and 18]) and either treated with 50 nM okadaic acid overnight (DNA samples 3 and 4 [lanes 3, 4, 9, 10, 15, and 16]) or left untreated (DNA samples 1 and 2 [lanes 1, 2, 7, 8, 13, and 14]). After 24 h of transfection, total cell RNA was prepared (see Materials and Methods) and RT was performed with 1 µg of total RNA primed with oligo(dT) by SuperScriptase II (lanes 1 to 6 and 13 to 18). PCR was carried out with two primers derived from luciferase (lanes 1 to 12) or GAPDH as a control for RNA input (lanes 13 to 18). A PCR without template DNA was also included (lane 19). RNA samples that were not reverse transcribed were also used as templates for luciferase PCR to check the level of plasmid contamination (lanes 7 to 12).

View larger version (28K): [in this window] [in a new window]   FIG. 9.   IEF-SDS-PAGE analysis of eIF4E phosphorylation in 2fTGH cells. 2fTGH cells were either left untreated (panel 1), treated with 25 nM okadaic acid (OA) for 20 h (panel 2), transfected with B56 expression plasmid DNA pZeoSV-B56 (panel 3), or transfected with pZeoSV-B56 and then treated with 100 µg of pIC per ml for 1 h (panel 4). Cells were lysed, and proteins from 300 µg of cell extract were separated with IEF-SDS-PAGE two-dimensional electrophoresis. eIF4E protein was detected by Western blotting using a monoclonal antibody against rabbit eIF-4E. Phosphorylated eIF4E has a lower isoelectric point and migrates to a lower pH position than unphosphorylated eIF4E.

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

PKR is an established eIF2 kinase and plays an important role in translational control. In fact, thus far, eIF2 is the only well-known physiological substrate established in vivo for PKR. However, there is an increasing amount of evidence supporting a role for PKR in different cellular activities, including transcription, apoptosis, and tumorigenesis. Therefore, it is likely that there are other physiologically important substrates for PKR. Identifying such substrates has become a primary obstacle in understanding PKR function, but yeast two-hybrid screening has provided a powerful tool to obtain interacting proteins (34). However, obtaining proteins which interact with active PKR by using yeast two-hybrid screening has been precluded because of the growth-inhibitory characteristics of PKR. Recently we described a PKR mutant with reduced kinase activity that retained wild-type affinity for eIF2 (7). Using this mutant in a two-hybrid screening has allowed us to identify two novel substrates for PKR, DRBP76 (43) and B56.

B56 is a cytosolic member of B' (B56) family and is expressed ubiquitously in many cell types (37). Compared to eIF2, B56 exhibits different features in its phosphorylation by PKR in vitro. B56 does not interact with or become phosphorylated efficiently by PKR unless PKR is activated by dsRNA (Fig. 1). Nevertheless, some constitutive association between PKR and B56 was observed in vivo (Fig. 3B and E), suggesting interaction likely reflecting basal PKR activity. The isolation of B56 by two-hybrid screening using the PKR M3 mutant with residual kinase activity supports this. The PKR-interacting domain on B56 may be distinct from the phosphorylation sites, since the PKR monoclonal antibody used in this study interferes with B56 phosphorylation by PKR (data not shown). In contrast, the phosphorylation of eIF2 is not affected by the monoclonal antibody (30).

B56 harbors multiple phosphorylation sites, and this is indicated from both in vitro B56 tryptic phosphopeptide mapping and in vivo B56 IEF-SDS-PAGE two-dimensional analysis. Although B56 is phosphorylated by PKR at S28 in vitro (Fig. 2), whether it is a physiological phosphoacceptor in vivo is not known. Since S28A mutant B56 retains the ability to be phosphorylated by PKR efficiently, the significance of phosphorylation of B56 by PKR at site S28 remains to be established. In vivo, B56 exhibits a wide range of isoelectric point values (pI 5.3 to 6.8 in murine fibroblasts [Fig. 4]), which may correspond to various phosphorylated states. Certainly PKR is not the only kinase that regulates the phosphorylation of B56, because in pkr-null cells B56 still exhibits differentially phosphorylated forms. Other kinases capable of phosphorylating B56 likely include PKC, PKA, and casein kinase II, since B56 has consensus sequences for these kinases. We confirmed that B56 is phosphorylated by PKC in vitro (data not shown). The regulation of B56 at multiple phosphoacceptor sites by different kinases suggests a previously unidentified mechanism by which kinases interact with PP2A.

There are two possible physiological consequences resulting from the interaction between PKR and B56. B56 may direct PP2A to dephosphorylate PKR, resulting in downregulation of PKR activity. PKR phosphorylation of B56 could cause either direct or indirect downregulation of PKR activity by activating dephosphorylation of PKR by PP2A. However, PKR is a poor substrate for PP2A (Fig. 6), and the major PKR phosphatase is likely PP1 (50). PKR dephosphorylation may be PP2A mediated in vivo, but cells transiently expressing B56 and treated with pIC showed no difference in the time course of PKR activation compared to untransfected cells (data not shown). Therefore, we concluded that it is unlikely that B56 directs PP2A to dephosphorylate PKR. PKR may phosphorylate B56 to regulate PP2A activity in vivo. The in vitro phosphatase assay demonstrated that phosphorylation of B56 by PKR could modulate PP2A activity, which was reflected by an increase in phosphatase activity on MBP and recombinant eIF2 (Fig. 5). However, direct evidence for PKR phosphorylation of B56 and modulation of PP2A activity is difficult to obtain due to PP2A dephosphorylating B56 (Fig. 6). Nevertheless, the alteration of PP2A activity by PKR shown indirectly by transfection assays in COS-1 cells and murine fibroblasts (Fig. 7) suggests an in vivo mechanism. Transiently expressed B56 can form trimeric PP2A either by interacting with free AC core dimer or by replacing other B subunits in the PP2A trimeric complex. This change in PP2A oligomeric forms could alter PP2A activity or localization. Overexpressing B56 causes an upregulation of protein synthesis. PKR inhibits this effect, probably by phosphorylating B56. A model can be proposed from these results which is based on PKR phosphorylation of B56 causing an increase in PP2A activity (Fig. 10). Increased PP2A activity likely affects different cellular activities including translation, transcription, apoptosis, and cell cycle regulation, processes in which PKR has also been implicated (reviewed in references 13 and 57).

View larger version (23K): [in this window] [in a new window]   FIG. 10.   Schematic model representing the modulation of PP2A activity by phosphorylation of B56 by PKR. PKR is activated by dsRNA and phosphorylates B56. Phosphorylation of B56 likely enhances enzymatic activity of the PP2Ac-B56 trimeric complex and alters cell activities by modulating the phosphorylation levels of downst